PUBLICATIONS 2007-2002
Prof. Dr. med. Dr. h.c. Kay Brune
(Publications in peer-reviewed journals)
2007
Polykandriotis E, Tjiawi J, Euler S, Arkudas A, Hess A, Brune K, Greil P, Lametschwandtner A, Horch RE,
Kneser U. The venous graft as an effector of early angiogenesis in a fibrin matrix. Microvasc Res.
2007 Apr 18; [Epub ahead of print]
N-terminal prohormone
brain natriuretic peptide: a biomarker for detecting cardiovascular risks in patients with
rheumatoid arthritis or osteoarthritis? Ann Rheum Dis. 2007 Jun;66(6):838-9.
Haupl T, Burmester GR, Giannitsis E, Rohrlach T, Spanuth E, Parsch H, Brune K.
Combining enzyme specificity and tissue selectivity of cyclooxygenase
inhibitors: towards better tolerability? Rheumatology (Oxford). 2007 Jun;46(6):911-9.
Brune K, Furst DE.
Renner B, Clarke G, Grattan T, Beisel A, Mueller C, Werner U, Kobal G, Brune K. Caffeine accelerates
absorption and enhances the analgesic effect of acetaminophen. J Clin Pharmacol. 2007
Jun;47(6):715-26.
Dipyrone elicits substantial
inhibition of peripheral cyclooxygenases in humans: new insights into the pharmacology of an
old analgesic. FASEB J. 2007 Apr 13; [Epub ahead of print]
Hinz B, Cheremina O, Bachmakov J, Renner B, Zolk O, Fromm MF, Brune K.
Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, Pahl A. Lipopolysaccharideinduced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol. 2007
28;557(2-3):230-5.
Brune K.
19.
Do case control studies on coxibs tell us anything new? Rheumatology (Oxford). 2007 Feb
Hinz B, Brune K.
[Pain therapy with antipyretic analgesics.] Orthopade. 2007 Jan;36(1):23-31.
Hinz B, Brune K Antipyretic analgesics:
nonsteroidal antiinflammatory drugs, selective COX-2
inhibitors, paracetamol and pyrazolinones. Handb Exp Pharmacol. 2007;(177):65-93.
Hess A, Sergejeva M, Budinsky L, Zeilhofer HU, Brune K.
functional MRI. Eur J Pain. 2007 Jan;11(1):109-19.
Imaging of hyperalgesia in rats by
2006
Hinz B, Brune K.
[Pain therapy with antipyretic analgesics.] Orthopade. 2006 Dec 15.
Synergistic effects of the anticholinergic R,R-glycopyrrolate with anti-inflammatory drugs. Biochem Pharmacol. 2006 Dec
Pahl A, Bauhofer A, Petzold U, Cnota PJ, Maus J, Brune K, Szelenyi S.
15;72(12):1690-6.
Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, Pahl A. Lipopolysaccharideinduced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol. 2006 Nov
14.
2
Are
computerised monitoring systems of value to improve pharmacovigilance in paediatric
patients? Eur J Clin Pharmacol. 2006 Nov;62(11):959-65.
Neubert A, Dormann H, Weiss J, Criegee-Rieck M, Ackermann A, Levy M, Brune K, Rascher W.
Polykandriotis E, Horch RE, Arkudas A, Labanaris A, Brune K, Greil P, Bach AD, Kopp J, Hess A, Kneser U.
Intrinsic versus extrinsic vascularization in tissue engineering. Adv Exp Med Biol. 2006;585:31126.
A validated high-performance liquid chromatographic assay for
determination of lumiracoxib in human plasma. Biomed Chromatogr. 2006 Oct;20(10):1033-7.
Cheremina O, Brune K, Hinz B.
Werner U, Lamprecht C, Werner D, Schaefer S, Wuttke H, Hinz B, Fromm MF, Brune K. Valdecoxib does
not interfere with the CYP2D6 substrate metoprolol. Int J Clin Pharmacol Ther. 2006 Sep;44(9):397400.
Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB In
vivo magnetic resonance imaging
of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol. 2006
Sep;36(9):2544-55.
Zeilhofer HU, Brune K. Analgesic strategies
Pharmacol Sci. 2006 Sep;27(9):467-74.
beyond the inhibition of cyclooxygenases. Trends
Kneser U, Polykandriotis E, Ohnolz J, Heidner K, Grabinger L, Euler S, Amann KU, Hess A, Brune K, Greil P,
Sturzl M, Horch RE. Engineering of vascularized transplantable bone tissues: induction of axial
vascularization in an osteoconductive matrix using an arteriovenous loop. Tissue Eng. 2006
Jul;12(7):1721-31.
Cardiovascular effects
of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. J
Crofford LJ, Breyer MD, Strand CV, Rushitzka F, Brune K, Farkouh ME, Simon LS.
Rheumatol. 2006 Jul;33(7):1403-8.
Kneser U, Polykandriotis E, Ohnolz J, Heidner K, Grabinger L, Euler S, Amann KU, Hess A, Brune K, Greil P,
Sturzl M, Horch RE. Engineering of Vascularized Transplantable Bone Tissues: Induction of
Axial Vascularization in an Osteoconductive Matrix Using an Arteriovenous Loop. Tissue Eng.
2006 May 1.
Hypoxia induced chemokine expression in nasal epithelial cells:
development of an in vitro model for chronic rhinosinusitis. ALTEX. 2006;23(2):59-63.
Pahl A, Szelenyi S, Brune K.
Zimmermann WH, Melnychenko I, Wasmeier G, Didie M, Naito H, Nixdorff U, Hess A, Budinsky L, Brune K,
Michaelis B, Dhein S, Schwoerer A, Ehmke H, Eschenhagen T. Engineered heart tissue grafts improve
systolic and diastolic function in infarcted rat hearts. Nat Med. 2006 Apr;12(4):452-8.
Determination of the endocannabinoid anandamide in human plasma
by high-performance liquid chromatography. Biomed Chromatogr. 2006 Apr;20(4):336-42.
Schmidt A, Brune K, Hinz B.
More pronounced inhibition of cyclooxygenase 2, increase in blood
pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib
and rofecoxib. Arthritis Rheum. 2006 Jan;54(1):282-91.
Hinz B, Dormann H, Brune K.
R(+)-methanandamide and other cannabinoids induce the
expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented
ciliary epithelial cells. J Pharmacol Exp Ther. 2006 Mar;316(3):1219-28.
Rosch S, Ramer R, Brune K, Hinz B.
3
R(+)-methanandamide elicits a cyclooxygenase2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. Pharm
Eichele K, Weinzierl U, Ramer R, Brune K, Hinz B.
Res. 2006 Jan;23(1):90-4.
2005
Prostaglandin E2 induces cyclooxygenase-2 expression in
human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogenactivated protein kinases. Biochem Biophys Res Commun. 2005 Dec 16;338(2):1171-8.
Rosch S, Ramer R, Brune K, Hinz B.
Determination of the endocannabinoid anandamide in human plasma
by high-performance liquid chromatography. Biomed Chromatogr. 2005 Sep 27; [Epub ahead of print]
Schmidt A, Brune K, Hinz B.
Latanoprost induces matrix metalloproteinase-1
expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2dependent mechanism. FASEB J. 2005 Nov;19(13):1929-31.
Hinz B, Rosch S, Ramer R, Tamm ER, Brune K.
Lamprecht C, Werner U, Werner D, Schaefer S, Renner B, Fromm M, Brune K. Effect of selective
cyclooxygenase-2 inhibitors on heart rate in healthy young men. Am J Cardiol. 2005 Jun
15;95(12):1531-2.
Simultaneous determination of
oxycodone and its major metabolite, noroxycodone, in human plasma by high-performance
liquid chromatography. Biomed Chromatogr. 2005 Dec;19(10):777-82.
Cheremina O, Bachmakov I, Neubert A, Brune K, Fromm MF, Hinz B.
Brune K. COX-2 selective inhibitors--they
Med Wkly. 2005 Mar 19;135(11-12):163-5.
are still the best treatment for many patients! Swiss
Chialda L, Zhang M, Brune K, Pahl A. Inhibitors of mitogen-activated protein kinases
differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia.
Respir Res. 2005 Apr 15;6(1):36.
Egger T, Dormann H, Ahne G, Pahl A, Runge U, Azaz-Livshits T, Neubert A, Criegee-Rieck
M, Gassmann KG, Brune K. Cytochrome p450 polymorphisms in geriatric patients: impact on
adverse drug reactions--a pilot study. Drugs Aging. 2005;22(3):265-72.
Reinold H, Ahmadi S, Depner UB, Layh B, Heindl C, Hamza M, Pahl A, Brune K, Narumiya
S, Muller U, Zeilhofer HU. Spinal inflammatory hyperalgesia is mediated by prostaglandin E
receptors of the EP2 subtype. J Clin Invest. 2005 Mar;115(3):673-9.
Hinz B, Chevts J, Renner B, Wuttke H, Rau T, Schmidt A, Szelenyi I, Brune K, Werner U.
Bioavailability of diclofenac potassium at low doses. Br J Clin Pharmacol. 2005 Jan;59(1):804.
Werner U, Werner D, Hinz B, Lambrecht C, Brune K. A liquid chromatography-mass
spectrometry method for the quantification of both etoricoxib and valdecoxib in human
plasma. Biomed Chromatogr. 2005 Mar;19(2):113-8.
4
Lamprecht C, Werner U, Werner D, Schaefer S, Renner B, Fromm M, Brune K. Effect of
selective cyclooxygenase-2 inhibitors on heart rate in healthy young men. Am J Cardiol. 2005
Jun 15;95(12):1531-2.
Cheremina O, Bachmakov I, Neubert A, Brune K, Fromm MF, Hinz B. Simultaneous
determination of oxycodone and its major metabolite, noroxycodone, in human plasma by
high-performance liquid chromatography. Biomed Chromatogr. 2005 May 26
2004
Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J
Rheumatol 2004, 33:1-6.
Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Troger M, Azaz-Livshits T,
Levy M, Brune K, Hahn EG. Readmissions and adverse drug reactions in internal medicine:
the economic impact. J Intern Med. 2004 Jun;255(6):653-63.
Ullmann S, Hage T, Draheim R, Egerland U, Oelmuller U, Brune K, Pahl A. RNA-Based
Drug Screening Using Automated RNA Purification and Real-time RT-PCR1. J Biomol
Screen. 2004 Apr;9(2):95-102.
Dormann H, Criegee-Rieck M, Neubert A, Egger T, Levy M, Hahn EG, Brune K.
Implementation of a computer-assisted monitoring system for the detection of adverse drug
reactions in gastroenterology. Aliment Pharmacol Ther. 2004 Feb 1;19(3):303-9.
Brune K, Hinz B. The Discovery and Development of Antiinflammatory Drugs. Arthritis
Rheum. 2004; 50(8):2391-2399.
Hinz B, Ramer R, Eichele K, Weinzierl U, Brune K. Upregulation of cyclooxygenase-2
expression is involved in R(+)-methanandamide-induced apoptotic death of human
neuroglioma cells. Mol Pharmacol. 2004 Sep 10
2003
Ates M, Hamza M, Seidel K, Kotalla C E, Ledent C, Gühring H, (Brune K). Intrathecally
applies flurbiprofen produces an endocannabinoid-dependent antinociception in the rat
formalin test. Eur J Neurosci. 2003 Feb;17(3):597-604.
Dormann H, Criegee-Rieck M, Neubert A, Egger T, Geise A, Krebs S, Schneider T, Levy M,
Hahn E, Brune K. Lack of awareness of community-acquired adverse drug reactions upon
hospital admission : dimensions and consequences of a dilemma. Drug Saf. 2003;26(5):35362.
Hinz B, Brune K, Pahl A. 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits the expression of
proinflammatory genes in human blood monocytes via a PPAR-gamma-independent
mechanism. Biochem Biophys Res Commun. 2003 Mar 7;302(2):415-20.
5
Hinz B, Auge D, Rau T, Rietbrock S, Brune K, Werner U. Simultaneous determination of
aceclofenac and three of its metabolites in human plasma by high-performance liquid
chromatography. Biomed Chromatogr. 2003 Jun;17(4):268-275.
Depner UB, Reinscheid RK, Takeshima H, Brune K, Zeilhofer HU. Normal sensitivity to
acute pain, but increased inflammatory hyperalgesia in mice lacking the nociceptin precursor
polypeptide or the nociceptin receptor. Eur J Neurosci. 2003 Jun;17(11):2381-2387.
Egger T, Dormann H, Ahne G, Runge U, Neubert A, Criegee-Rieck M, Gassmann KG,
Brune K. Identification of adverse drug reactions in geriatric inpatients using a computerised
drug database. Drugs Aging 2003, 20(10):769-76.
Werner U, Werner D, Rau T, Fromm M, Hinz B. Brune K. Celecoxib inhibits metabolism of
cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003, 74(2):
130-7.
Hinz B, Rau T, Auge D, Werner U, Ramer R, Rietbrock S, Brune K. Aceclofenac spares
COX-1 due to limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther
2003, 74(3):222-35.
Ramer R, Weinzierl U, Schwind B, Brune K, Hinz B. Ceramide is involved in r(+)methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol
Pharmacol. 2003 Nov;64(5):1189-98.
2002
Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the
pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed
Chromatogr. 2002 Feb;16(1):56-60.
Pahl A, Zhang M, Kuss H, Szelenyi I, Brune K. Regulation of IL-13 synthesis in human
lymphocytes: implications for asthma therapy. Br J Pharmacol. 2002 Apr;135(8):1915-26.
Pahl A, Zhang M, Torok K, Kuss H, Friedrich U, Magyar Z, Szekely J, Horvath K, Brune K,
Szelenyi I. Anti-inflammatory effects of a cyclosporine receptor-binding compound, D43787. J Pharmacol Exp Ther. 2002 May;301(2):738-46.
Schwartz JI, Vandormael K, Malice MP, Kalyani RN, Lasseter KC, Holmes GB, Gertz BJ,
Gottesdiener KM, Laurenzi M, Redfern KJ, Brune K. Comparison of rofecoxib, celecoxib,
and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin
Pharmacol Ther. 2002 Jul;72(1):50-61.
Simon LS, Smolen JS, Abramson SB, Appel G, Bombardier C, Brater DC, Breedveld FC,
Brune K, Burmester GR, Crofford LJ, Dougados M, DuBois RN, Fitzgerald GA, Frishman
W, Garcia Rodriguez LA, Hochberg MC, Kalden JR, Laine L, Langman MJ, Prescott SM,
van de Putte LB, Whelton A, White WB, Willaims GH (2002). Controversies in COX-2
selective inhibition. J Rheumatol. 2002 Jul;29(7):1501-10.
Pahl A, Brune K. Gene expression changes in blood after phlebotomy: implications for gene
expression profiling. Blood. 2002 Aug 1;100(3):1094-5.
6
Weiss J, Krebs S, Hoffmann C, Werner U, Neubert A, Brune K, Rascher W. Survey of
adverse drug reactions on a pediatric ward: a strategy for early and detailed detection.
Pediatrics. 2002 Aug;110(2 Pt 1):254-7.
Schmitt C, Humeny A, Becker CM, Brune K, Pahl A. Polymorphisms of TLR4: rapid
genotyping and reduced response to lipopolysaccharide of TLR4 mutant alleles.
Clin Chem. 2002 Oct;48(10):1661-7.
Guhring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, Brune K. A role for
endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol. 2002
Nov 15;454(2-3):153-63.
Pahl A, Brune K. Stabilization of gene expression profiles in blood after phlebotomy.
Clin Chem. 2002 Dec;48(12):2251-3.
Hinz B, Brune K. Cyclooxygenase-2 - 10 Years Later. J Pharmacol Exp Ther 2002,
300(2):367-75.
Brune K. Next generation of everyday analgesics. Am J Ther. 2002 May-Jun;9(3):215-23.